| gap-pubmed-20260410- | What are the specific molecular mechanisms by which indoxyl sulfate disrupts neu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does intracerebroventricular indoxyl sulfate cause only limited CNS alterati | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do brain connectivity changes relate to actual CNS bioavailability of GLP-1 | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do GLP-1 RAs reproducibly engage neural targets that mediate cognitive functions | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms enable selective GLP-1 RAs to cross the blood-brain barrier whil | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do Ca2+ dysregulation and amyloid pathways interact in AD pathogenesis? | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why have all amyloid cascade-targeting drugs failed despite strong mechanistic r | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which PS2 mutations alter multiple | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do acute versus chronic sleep loss differentially affect regional brain Aβ d | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does sleep deprivation-induced Aβ accumulation correlate with mood changes b | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What cellular mechanisms drive rapid Aβ accumulation in hippocampus and thalamus | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines which housekeeping gene promoters are selected for Ronin-mediate | open | 0.72 | 0.00 | 2026-04-10 | 0 | | gene-regulation |
| gap-pubmed-20260410- | How does Ronin mechanistically assemble multiple promoters to form functional re | open | 0.77 | 0.00 | 2026-04-10 | 0 | | gene-regulation |
| gap-pubmed-20260410- | What determines the specific composition of heterogeneous tau lesions within ind | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the diversity of neuronal and glial tau pathology across d | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What neurobiological mechanisms explain why depression predicts injury but anxie | open | 0.69 | 0.00 | 2026-04-10 | 0 | | behavioral-neuroscience |
| gap-pubmed-20260410- | Why does work-related injury have a protective effect against anxiety developmen | open | 0.73 | 0.00 | 2026-04-10 | 0 | | stress-neurobiology |
| gap-pubmed-20260410- | What drives the bidirectional relationship between tau pathology and altered sle | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does sleep deprivation mechanistically link reduced microglial clustering to | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms explain why APOE4 but not APOE3 sensitizes to sleep di | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines tissue-specific alternative splicing patterns of TARDBP in ALS v | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do specific TARDBP splice variants mechanistically contribute to TDP43 prote | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why doesn't mild cognitive impairment strongly predict synucleinopathy conversio | open | 0.71 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link olfactory loss and color vision deficits to synucleinopathy | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does antidepressant use protect against synucleinopathy conversion in RBD pa | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What amyloid threshold level is required for optimal clinical benefit in early A | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does amyloid reduction correlate with tau biomarkers but not neurofilament l | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the temporal coordination between ubiquitination and autophagy i | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does kaempferol selectively promote autophagy in microglia versus other CNS | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What specific ubiquitin ligases and deubiquitinases regulate NLRP3 targeting for | resolved | 0.84 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does MEF2C loss affect neuronal differentiation but spare NSC proliferation | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | How does MEF2C dysfunction specifically lead to Rett syndrome-like behavioral ph | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodevelopmental-disorders |
| gap-pubmed-20260410- | What molecular mechanisms does MEF2C use to control neuronal differentiation and | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What mechanisms link traumatic brain injury to the development of aging-like and | resolved | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can CTE be distinguished from AD/aging tauopathies if their tau immunophenot | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do astroglial and neurofibrillary tau pathologies in CTE have distinct immun | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the optimal therapeutic sequence for targeting H. pylori, MetS, and mast | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do meningeal mast cells specifically contribute to neurodegeneration versus | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which H. pylori and MetS trigger m | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How broadly applicable is complement inhibition for preventing synapse loss acro | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What determines selective C3 versus C1q complement activation at synapses in dem | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does synapse loss occur independently of local demyelination in MS? | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do some SORL1 variants not affect SorLA trafficking despite being associated | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Can CSF sSorLA levels predict functional consequences of the remaining 75% of SO | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms cause trafficking-defective SORL1 variants to reduce s | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do the isoform pairing requirements for tau prion propagation observed in cell c | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanism allows high 4R tau expression alone to support propagation of mix | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do AD and CTE tau prions fail to robustly infect single isoform-expressing c | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link epigenetic Syk expression changes to retinoblastoma develop | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does 3BP2 adaptor protein function as a target of Syk in neurological contex | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |